- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hodgkin lymphoma
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 849KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 530KB)
Brentuximab vedotin – March 2024
Brentuximab Vedotin: Powder for I.V. infusion 50 mg; Adcetris®
Last updated
30 May 2025